Healthcare · Hospital/Nursing Management
| Year | Revenue | Net profit | EPS |
|---|---|---|---|
| 2026 | Rs 11.0B | Rs 1.1B | 5.68 |
| 2025 | Rs 9.8B | Rs 726.0M | 16.38 |
| 2024 | Rs 9.2B | Rs 453.8M | 11.59 |
| 2023 | Rs 7.9B | Rs 651.7M | 16.88 |
| 2022 | Rs 7.8B | Rs 1.1B | 29.00 |
| 2021 | Rs 5.5B | Rs 600.3M | 16.54 |
| 2020 | Rs 6.0B | Rs 467.1M | 11.91 |
Ceylon Hospitals PLC (Durdans) is a Sri Lanka-based private healthcare group that provides hospital-based care and an expanding network of diagnostic and laboratory services. The Group's narrative focuses on delivering inpatient, outpatient and day-case care alongside specialised clinical services supported by surgical and diagnostic capabilities. Operations include the main Durdans hospital and an islandwide laboratory and diagnostics network, complemented by education and workforce development through the Amrak Institute of Medical Sciences and related subsidiaries. Named subsidiaries in the Group scope include Durdans Medical & Surgical Hospital (Pvt) Ltd, Amrak Institute of Medical Sciences (Pvt) Ltd and Ceygen Biotech (Pvt) Ltd. The Group operates across Sri Lanka with its head office in Colombo and has expanded services into regions including Galle and Kurunegala, maintaining standards aligned with international accreditation and pursuing digital and service expansion initiatives.
No AI research report for Ceylon Hospitals Plc yet. Generate one from everything we track: prices, valuation, news sentiment, financials and corporate actions.
Generate an analysis →No scored news in the last 30 days.
Dividend · Rs 1.10 · XD Jun 1, 2026
First Interim dividend of LKR 1.1/share; XD 2026-06-01; record 2026-06-01; payable 2026-06-18; FY 31st March 2026
Share split · 1:4 · XD Mar 5, 2026
Ceylon Hospitals (Durdans) will seek shareholder approval to subdivide voting shares from 31,762,723 to 127,050,892 and non-voting shares from 10,133,765 to 40,535,060 (1-for-4); stated capital will remain at 1,778,802,331.50 rupees and the plan is pending regulatory approval.
Ceylon Hospitals (Durdens) will propose a 4-for-1 subdivision of both ordinary voting and non-voting shares, subject to regulatory and shareholder approvals. Voting shares would rise to 127,050,892 and non-voting to 40,535,060, with stated capital unchanged at Rs. 1,778,802,331.50.
Share split · 1:4 · XD Mar 5, 2026
Split issue
Dividend · Rs 4.00 · XD Jun 23, 2025
First Interim dividend of LKR 4/share; XD 2025-06-23; record 2025-06-23; payable 2025-07-11; FY 31st March 2025
Ceylon Hospitals PLC appointed Lasantha Karunasekara as CEO effective Jan 1. He has over 22 years' experience including as Deputy CEO/Director Medical Services at Lanka Hospitals; Ceylon Hospitals shares were reported trading at 123.50 (ordinary) and 99.00 (non-voting).
SLPMA dominated sector news, urging a long-term government buyback to back local pharma manufacturing, quicker raw-material import approvals and stable incentives, plus a national push to make pharmaceuticals an export engine through a task force and faster regulation. Cross-border activity featured a 31-member Indian delegation on 8-10 July for B2B sessions including pharma. Colombo Port City moved to seek operators for an international hospital. Cybersecurity risks to hospitals gained attention.
Auto-generated from 8 sector news articles over 30 days. Not investment advice. 2 more stories on the sentiment page.